Previous 10 | Next 10 |
2023-07-17 13:21:00 ET Complete phase 3 data released on Eli Lilly's ( NYSE: LLY ) donanemab confirmed that the Alzheimer's biologic was effective in slowing cognitive decline in early stages of the disease compared to placebo. Yet, as is the case with Biogen ( BIIB ) and Ei...
2023-07-17 10:00:46 ET Shares of Acumen Pharmaceuticals ( NASDAQ: ABOS ) rallied more than 60% in early trading Monday in the wake of the release of positive data from a Phase 1 clinical trial for its Alzheimer's disease drug candidate ACU193. Acumen shares opened at a $6.11, re...
2023-07-17 09:45:00 ET With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling biotech stock? On the positive side, the company's ne...
2023-07-16 12:00:00 ET While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later this month, Barclays has picked Eli Lilly ( NYSE: LLY ) and Merck ( NYSE: MRK ) as two of the most favorably positioned ...
2023-07-16 07:15:00 ET Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for the therapy to bring in $12.9 billion in sales annually throug...
2023-07-13 08:15:00 ET Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't surge to new heights, and it actually declined. Here's why inv...
2023-07-13 08:03:58 ET Summary Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique binding profile. Results of the ...
2023-07-11 08:14:36 ET ADC Therapeutics ( NYSE: ADCT ) lost ~16% pre-market Tuesday after announcing a voluntary pause in enrollments in a Phase 2 trial for a drug regimen containing its lymphoma therapy Zynlonta due to treatment-emergent adverse events (TEAEs). The study, L...
2023-07-10 16:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-09 23:52:19 ET Summary The FDA has granted full approval to Biogen and Eisai’s anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The approval led to a drop in Biogen's stock, in part due to the FDA's warning about potential s...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...